Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LISATA THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for LISATA THERAPEUTICS, INC.

LSTA

LISATA THERAPEUTICS, INC.

About LISATA THERAPEUTICS, INC.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for solid tumors and major diseases. Its lead investigational drug, certepetide, enhances delivery and efficacy of anti-cancer treatments by activating a tumor-specific transport pathway. The company targets cancers like pancreatic ductal adenocarcinoma, leveraging its proprietary CendR platform to improve treatment outcomes through combination therapies and collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from LISATA THERAPEUTICS, INC.

1
1
LISATA THERAPEUTICS, INC. Lisata Therapeutics Reports Q1 2026 Financial Results with $4.5M Net Loss

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
LISATA THERAPEUTICS, INC. Lisata Therapeutics Reports $16.6 Million Net Loss, Announces Proposed Acquisition by Kuva Labs

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
LISATA THERAPEUTICS, INC. Lisata Therapeutics Reports Q3 2025 Financial Results with $4.2M Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
LISATA THERAPEUTICS, INC. Lisata Therapeutics Reports $70,000 Revenue and $4.7 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
LISATA THERAPEUTICS, INC. Lisata Therapeutics Reports $4.7 Million Net Loss in Q1 2025, Focuses on Certepetide Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
LISATA THERAPEUTICS, INC. Lisata Therapeutics Reports Third Quarter and Nine Months Financial Results, Focuses on Clinical Development Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments